Nuance Pharma (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-08-12
- Employees
- 11
- Market Cap
- -
- Website
- https://www.nuancepharma.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 3
1 (25.0%)A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT05758428
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 526
- Registration Number
- NCT05743075
- Locations
- 🇨🇳
1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT05382546
- Locations
- 🇨🇳
HUK Phase 1 clinical trials center, Hong Kong, Hong Kong, China
Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT04158102
- Locations
- 🇨🇳
HUK Phase 1 clinical trials center, Hong Kong, Hongkong, China
News
No news found